{"gene":"UBA5","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2010,"finding":"Crystal structure of human UBA5 bound to ATP revealed that the catalytic cysteine (Cys250) is located within the adenylation domain in an alpha-helical motif, unlike other E1 enzymes where the active-site cysteine is in a separate flexible domain. Conformational changes associated with ATP binding provide insight into ubiquityl-enzyme thioester formation.","method":"X-ray crystallography with structural comparison to canonical E1 enzymes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure solved with functional mechanistic interpretation, published in rigorous journal","pmids":["20368332"],"is_preprint":false},{"year":2014,"finding":"UBA5 activates UFM1 via a two-step mechanism forming a binary covalent UBA5~UFM1 thioester (contrasting with Uba1's three-step ternary mechanism). UBA5 shows random ordered binding with UFM1 and ATP. Binding of ATP to the UBA5~UFM1 thioester is required for efficient transthiolation of UFM1 to UFC1. The pan-E1 inhibitor adenosine 5'-sulfamate (ADS) reacts with the UBA5~UFM1 thioester to form a tight-binding Ufm1-ADS adduct.","method":"In vitro thioester formation assay, ATP-PPi exchange assay, mechanism-based inhibitor studies, cellular assays in HCT116 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical assays including reconstitution and mechanistic inhibitor probes in a single rigorous study","pmids":["24966333"],"is_preprint":false},{"year":2016,"finding":"Crystal structure of the homodimeric UBA5 in complex with UFM1 revealed a trans-binding mechanism: UFM1 interacts with distinct sites on both subunits of the UBA5 dimer, requiring the C-terminal region to bring UFM1 to the active site of the adjacent subunit. Transfer of UFM1 from UBA5 to UFC1 (E2) also occurs via a trans mechanism requiring a UBA5 homodimer.","method":"X-ray crystallography of UBA5-UFM1 complex, supporting biochemical experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with biochemical validation of the trans mechanism","pmids":["27653677"],"is_preprint":false},{"year":2016,"finding":"A combined LIR/UFIM motif at the C-terminus of UBA5 enables binding to both UFM1 and LC3/GABARAP proteins. This motif is required for full biological activity of UBA5 and for effective transfer of UFM1 onto UFC1 and downstream substrate proteins, both in vitro and in cells.","method":"NMR structure determination, binding assays, in vitro transfer assays, cellular functional assays with mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural determination combined with in vitro and cellular functional assays using mutants","pmids":["26929408"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of UFM1 fused to 13 amino acids of human UBA5 refined the UFM1-interacting sequence (UIS) boundaries. His336 of UBA5, not previously identified as part of the UIS, occupies a negatively charged pocket on UFM1's surface and is required for UFM1 binding and activation when mutated. A UFM1-UFM1 interaction was found to mimic UIS binding.","method":"X-ray crystallography, binding assays, UFM1 activation activity assays with mutagenesis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with mutagenesis-validated binding and activity assays","pmids":["28360427"],"is_preprint":false},{"year":2018,"finding":"Trans-binding of UFM1 to UBA5 stabilizes the UBA5 homodimer, and UBA5 dimerization is required for ATP binding. UFM1 binding therefore enhances UBA5 affinity for ATP, establishing a regulatory connection between UFM1 engagement and ATP binding by UBA5.","method":"Biochemical binding and activity assays, biophysical analysis of dimerization","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical methods in single lab demonstrating mechanistic connection","pmids":["29295865"],"is_preprint":false},{"year":2018,"finding":"The N-terminal extension present in the longer UBA5 isoform directly participates in ATP binding and changes the stoichiometry from 1:2 to 1:1 (ATP:UBA5), significantly increases UBA5 affinity for ATP, and stimulates transfer of UFM1 from UBA5 to UFC1 despite not being directly involved in E2 binding.","method":"Crystal structures of long UBA5 isoform ± UFM1 with ATP, biochemical ATP binding and UFM1 transfer assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures with biochemical validation in a single focused study","pmids":["30412706"],"is_preprint":false},{"year":2019,"finding":"The non-canonical LIR motif of UBA5 preferentially interacts with GABARAP over LC3 proteins via an additional conserved tryptophan binding into a novel hydrophobic pocket (HP0) on GABARAP surface, with K/R47 in GABARAP as the key specificity residue. GABARAP proteins regulate UBA5 localization and function on the endoplasmic reticulum membrane in a lipidation-independent manner.","method":"NMR and X-ray crystal structures of GABARAP/GABARAPL2-UBA5 LIR complexes, swapping mutagenesis, isothermal titration calorimetry, live cell imaging/fractionation","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal/NMR structures, mutagenesis, and functional localization assays","pmids":["30990354"],"is_preprint":false},{"year":2021,"finding":"Crystal structure of UFC1 bound to the C-terminus of UBA5 revealed a short linear sequence mediating the UBA5-UFC1 interaction not observed in other E1-E2 complexes. A region outside the adenylation domain of UBA5 is dispensable for UFC1 binding but critical for UFM1 transfer, moving next to UFC1's active-site Cys to compensate for a missing loop in UFC1.","method":"X-ray crystallography of UBA5 C-terminus–UFC1 complex, biochemical UFM1 transfer assays with truncation/mutagenesis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis-validated transfer mechanism","pmids":["34588452"],"is_preprint":false},{"year":2021,"finding":"The last 20 residues of the C-terminal unstructured region of UBA5 are pivotal for binding to UFC1 and accelerate UFM1 transfer to UFC1. NMR structure of UFC1 bound to the last 20 residues of UBA5 revealed the molecular basis of this interaction.","method":"NMR spectroscopy of UFC1-UBA5 C-terminal peptide complex, isothermal titration calorimetry, biochemical transfer assays","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with ITC and biochemical activity assays","pmids":["34299007"],"is_preprint":false},{"year":2021,"finding":"UFM1 regulates the oligomeric state of UBA5: mixtures of homodimers and heterotrimers are observed in solution, with the UBA5-UFM1 complex undergoing concentration-dependent oligomeric transitions. UBA5 alone transitions from monomeric to dimeric in a concentration-dependent manner with negative cooperativity in complex formation.","method":"Small-angle X-ray scattering (SAXS), binding studies, biophysical characterization of oligomeric states","journal":"Journal of structural biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — SAXS-based structural analysis, single lab, single study","pmids":["34508858"],"is_preprint":false},{"year":2022,"finding":"Overexpression of UBA5 (but not UFC1) reverses the trans-thiolation reaction, causing back-transfer of UFM1 from UFC1 to UBA5, thereby reducing charged UFC1 levels and impairing ufmylation. This overexpression phenocopies UBA5 or UFC1 loss in impairing cell migration. Co-expression with UFM1 abolishes the back-transfer, indicating that free UFM1 concentration controls directionality.","method":"Biochemical thioester assays, cell migration assays with overexpression and knockout lines","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical and cellular assays with multiple genetic conditions in single lab","pmids":["35806453"],"is_preprint":false},{"year":2011,"finding":"Uba5 is the specific E1-activating enzyme for UFM1 and is indispensable for erythroid differentiation in mice. Genetic loss of Uba5 impairs development of megakaryocyte and erythroid progenitors from common myeloid progenitors, causing severe anemia and embryonic death. Transgenic erythroid-specific re-expression of Uba5 rescued anemia, demonstrating cell-autonomous function.","method":"Conditional knockout mouse model, transgenic rescue, colony-forming assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with transgenic rescue demonstrating cell-autonomous mechanism, published in high-impact journal","pmids":["21304510"],"is_preprint":false},{"year":2016,"finding":"UBA5 mutations causing early-onset encephalopathy impair ufmylation and result in abnormal endoplasmic reticulum structure in patient fibroblasts. In C. elegans, knockout of uba-5 and UFM1 cascade orthologs alters cholinergic but not glutamatergic neurotransmission. In zebrafish, uba5 silencing decreases motility and induces seizure-like movements.","method":"Biochemical ufmylation assays in patient fibroblasts, C. elegans knockout behavioral assays, zebrafish morpholino knockdown","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — orthogonal model systems with functional assays, multiple cell and organism-level readouts","pmids":["27545681"],"is_preprint":false},{"year":2016,"finding":"The UBA5 p.Ala371Thr variant is hypomorphic, with attenuated ability to transfer activated UFM1 to UFC1 as shown by in vitro thioester formation assay. CNS-specific knockout of Ufm1 in mice causes neonatal death with microcephaly and apoptosis in specific neurons.","method":"In vitro thioester formation assay, conditional CNS Ufm1 knockout mouse model","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro biochemical assay with mutagenesis combined with genetic mouse model","pmids":["27545674"],"is_preprint":false},{"year":2016,"finding":"UBA5-R246X mutation dramatically decreases protein half-life and abolishes UFM1 activation due to loss of the catalytic Cys250. UBA5-K310E maintains UFM1 interaction with reduced stability. In Drosophila, UBA5 knockdown induces locomotor defects, shortened lifespan, and aberrant neuromuscular junctions; wild-type but not mutant UBA5 restores neural lesions.","method":"Protein stability assays, UFM1 activation assays, Drosophila genetic rescue with wild-type vs. mutant UBA5","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical assays and genetic rescue in Drosophila model with mutant-specific comparisons","pmids":["26872069"],"is_preprint":false},{"year":2008,"finding":"UBA5 (UBE1DC1) activates not only UFM1 but also SUMO2 in vitro and in vivo by forming a high-energy thioester bond. UBA5 localizes predominantly to the cytoplasm, but redistributes to the nucleus upon co-transfection with SUMO2.","method":"In vitro thioester assay, in vivo co-immunoprecipitation, immunofluorescence subcellular localization in AD293 cells","journal":"Journal of cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, SUMO2 activation finding not widely replicated; subcellular localization by single method","pmids":["18442052"],"is_preprint":false},{"year":2017,"finding":"A covalent ligand (DKM 2-93) that modifies the catalytic cysteine of UBA5 inhibits its activity as an E1 enzyme for UFM1, impairs pancreatic cancer cell survival, and reduces in vivo tumor growth, identifying UBA5 catalytic cysteine as a druggable hotspot.","method":"isoTOP-ABPP chemoproteomic platform, covalent ligand screening, in vitro activity assays, cell viability assays, xenograft tumor models","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — chemoproteomic target identification with biochemical and in vivo functional validation","pmids":["28186401"],"is_preprint":false},{"year":2023,"finding":"Systematic biochemical assays across UBA5 disease variants established an allelic series with mild, intermediate, and severe loss-of-function grades based on protein stability, ATP binding, UFM1 activation, and UFM1 transthiolation. In vivo Drosophila phenotypes (viability, lifespan, locomotion) strongly correlate with in vitro biochemical severity.","method":"Comprehensive in vitro biochemical assays (thermal stability, ATP binding, UFM1 charging, transthiolation), humanized Drosophila UBA5 model","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical assays combined with in vivo genetic model across allelic series","pmids":["38079206"],"is_preprint":false},{"year":2026,"finding":"UBA5 loss disrupts mitochondrial quality control: UBA5-deficient cells accumulate damaged mitochondria and increased ROS. The PINK1-Parkin damage response is engaged but mitophagy execution is inefficient, resulting in impaired clearance of dysfunctional mitochondria, p53 activation, DNA damage responses, p21-associated G2/M arrest, and early apoptosis.","method":"UBA5 knockout cells, mitochondrial morphology assays, ROS measurement, mitophagy flux assays, cell cycle analysis, apoptosis assays","journal":"Biological research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple cellular assays in single study but limited mechanistic depth on UFMylation-PINK1/Parkin connection","pmids":["41645284"],"is_preprint":false},{"year":2025,"finding":"UFMylation downstream of UBA5 promotes non-homologous end-joining (NHEJ) DNA double-strand break repair. Ku70 is identified as a UFMylation substrate; UFMylated Ku70 is recognized by XRCC4 to promote chromatin assembly of NHEJ factors. Perturbation via a hypomorphic UBA5 allele in patient-derived fibroblasts impairs these processes.","method":"Photo-crosslinkable UFM1 probe, high-resolution NMR, proximity-dependent proteomics, patient-derived fibroblast functional assays, UFSP2 depletion","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — multiple sophisticated methods but preprint, single study, not yet peer-reviewed","pmids":["bio_10.1101_2025.06.16.659844"],"is_preprint":true},{"year":2025,"finding":"UBA5 function is required for orthoflavivirus (dengue, Zika, West Nile, yellow fever) replication. UFMylation pathway components including UBA5 are selectively recruited to viral replication sites; UFMylation promotes mitochondrial respiration in this context. Pharmacological inhibition of UFMylation reduces viral replication in vitro and in vivo.","method":"Proteomic interaction mapping, siRNA knockdown of UFMylation components, pharmacological inhibition, in vitro and in vivo viral replication assays","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, UBA5-specific mechanistic detail is limited relative to broader UFMylation pathway findings","pmids":["bio_10.1101_2025.05.15.653649"],"is_preprint":true},{"year":2025,"finding":"Patient-derived cortical organoids with compound heterozygous UBA5 pathogenic variants show defects in GABAergic interneuron development, aberrant neuronal firing, and reduced organoid size. ER homeostasis is perturbed and the unfolded protein response pathway is exacerbated in cells and organoids expressing UBA5 pathogenic variants.","method":"Patient-derived cortical organoid culture, single-cell RNA sequencing, electrophysiology, UPR pathway assays","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — humanized patient-derived model with multiple cellular readouts and mechanistic ER stress pathway analysis","pmids":["40333994"],"is_preprint":false},{"year":2014,"finding":"UBA5 residues 381–404 constitute the minimal region for UFC1 recognition, while residues 364–404 are necessary for transthiolation of UFM1 to UFC1. The UBA5–UFC1 fusion protein exists as a homodimer in solution.","method":"Truncation assays, protein biochemistry, crystallization/preliminary X-ray analysis","journal":"Acta crystallographica Section F","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — defined minimal binding region by truncation with structural corroboration, single study","pmids":["25084390"],"is_preprint":false}],"current_model":"UBA5 is the sole E1-activating enzyme for UFM1 that functions as a homodimer using a two-step (binary thioester) mechanism distinct from canonical E1 enzymes: its catalytic Cys250 resides within the adenylation domain, UFM1 binds in trans across the dimer interface stabilizing dimerization and enhancing ATP binding, a C-terminal region (residues 381–404) mediates UFC1 binding and UFM1 transthiolation via an unconventional short linear motif, and an atypical LIR/UFIM motif targets UBA5 to the ER membrane through GABARAP interaction; loss of UBA5 activity causes ER stress, impaired mitophagy, defective erythroid differentiation, and aberrant neurodevelopment including GABAergic interneuron defects."},"narrative":{"mechanistic_narrative":"UBA5 is the sole E1-activating enzyme that initiates the UFM1 conjugation (ufmylation) cascade, an essential post-translational modification system required for erythroid development, neurodevelopment, ER homeostasis, and genome maintenance [PMID:21304510, PMID:24966333]. It activates UFM1 through an unconventional two-step mechanism that forms a binary covalent UBA5~UFM1 thioester on its catalytic Cys250, which uniquely resides within the adenylation domain rather than a separate cysteine-bearing domain as in canonical E1 enzymes [PMID:20368332, PMID:24966333]. UBA5 functions as a homodimer that engages UFM1 in trans: UFM1 binds distinct sites across both subunits, stabilizing dimerization and enhancing ATP binding, and the C-terminal region delivers UFM1 to the active site of the adjacent subunit for transthiolation onto the E2 enzyme UFC1 [PMID:27653677, PMID:29295865]. A short linear motif in the C-terminal unstructured region (residues 381–404) mediates UFC1 recognition and positions UBA5 next to UFC1's active-site cysteine to drive UFM1 transfer, while an atypical combined LIR/UFIM motif binds both UFM1 and GABARAP, the latter targeting UBA5 to the ER membrane independent of lipidation [PMID:34588452, PMID:25084390, PMID:30990354, PMID:26929408]. Downstream of this cascade, UFM1 is conjugated to substrates including Ku70 to promote non-homologous end-joining DNA repair [PMID:bio_10.1101_2025.06.16.659844]. Loss of UBA5 activity impairs ufmylation and produces ER stress and an exacerbated unfolded protein response, defective mitochondrial quality control with inefficient PINK1-Parkin mitophagy, defective erythroid differentiation, and aberrant neurodevelopment with GABAergic interneuron defects [PMID:40333994, PMID:41645284, PMID:21304510]. Biallelic hypomorphic and loss-of-function UBA5 variants form a graded allelic series whose biochemical severity correlates with early-onset encephalopathy phenotypes [PMID:38079206, PMID:27545681].","teleology":[{"year":2008,"claim":"Established UBA5 as a thioester-forming activating enzyme, the founding observation of its E1 catalytic capacity, though with disputed substrate breadth.","evidence":"In vitro thioester assay, co-immunoprecipitation and immunofluorescence in AD293 cells","pmids":["18442052"],"confidence":"Low","gaps":["SUMO2 activation not widely replicated and conflicts with later UFM1-specific consensus","subcellular localization assessed by single method"]},{"year":2010,"claim":"Resolved why UBA5 is mechanistically atypical by placing its catalytic Cys250 within the adenylation domain rather than a separate cysteine domain, distinguishing it from canonical E1 enzymes.","evidence":"X-ray crystallography of human UBA5–ATP with comparison to canonical E1 enzymes","pmids":["20368332"],"confidence":"High","gaps":["structure did not capture the UFM1-bound or transthiolation state","dimeric trans mechanism not yet resolved"]},{"year":2011,"claim":"Defined the physiological requirement for UBA5/UFM1 by showing it is indispensable and cell-autonomous for erythroid differentiation, establishing the pathway's developmental importance.","evidence":"Conditional knockout mouse with erythroid-specific transgenic rescue and colony-forming assays","pmids":["21304510"],"confidence":"High","gaps":["molecular ufmylation substrates in erythropoiesis not identified","does not address neuronal phenotypes"]},{"year":2014,"claim":"Defined the kinetic logic of UFM1 activation, showing a two-step binary thioester mechanism with ATP-dependent transthiolation, and mapped the minimal UFC1-binding C-terminal region.","evidence":"In vitro thioester and ATP-PPi exchange assays, mechanism-based inhibitor probes, truncation analysis with HCT116 cellular assays","pmids":["24966333","25084390"],"confidence":"High","gaps":["structural basis of UFM1-to-UFC1 transfer not yet visualized","regulation of reaction directionality undefined"]},{"year":2016,"claim":"Revealed that UBA5 operates as a homodimer engaging UFM1 in trans across the dimer interface, explaining how a single-domain E1 catalyzes both activation and transfer.","evidence":"X-ray crystallography of the UBA5–UFM1 complex with biochemical validation, plus refined UIS boundaries by additional crystallography and mutagenesis","pmids":["27653677","28360427"],"confidence":"High","gaps":["dynamics of oligomeric transitions in solution not resolved","coupling between dimerization and catalysis quantitatively undefined"]},{"year":2016,"claim":"Connected UBA5 to membrane targeting by defining a combined LIR/UFIM motif that binds both UFM1 and LC3/GABARAP and is required for full activity.","evidence":"NMR structure, binding assays, and in vitro/cellular transfer assays with mutagenesis","pmids":["26929408"],"confidence":"High","gaps":["functional consequence of ER localization not yet defined","selectivity among ATG8 family members not yet resolved"]},{"year":2016,"claim":"Linked UBA5 to human disease by showing patient mutations impair ufmylation and disrupt ER structure, with model-organism phenotypes establishing a neurological role.","evidence":"Ufmylation assays in patient fibroblasts, C. elegans knockout behavior, zebrafish knockdown, in vitro thioester assays of variants, CNS Ufm1 mouse knockout","pmids":["27545681","27545674","26872069"],"confidence":"Medium","gaps":["genotype–phenotype severity relationship not yet systematized","neuronal substrates of ufmylation unidentified"]},{"year":2017,"claim":"Established UBA5 as a druggable target by showing covalent modification of its catalytic cysteine blocks UFM1 activation and impairs cancer cell survival and tumor growth.","evidence":"isoTOP-ABPP chemoproteomics, covalent ligand screening, activity and viability assays, xenograft models","pmids":["28186401"],"confidence":"High","gaps":["selectivity over other cysteine-active enzymes not exhaustively characterized","downstream ufmylation substrates mediating anti-tumor effect unknown"]},{"year":2018,"claim":"Defined regulatory coupling whereby UFM1 binding stabilizes the dimer and the long-isoform N-terminal extension tunes ATP affinity and stoichiometry, linking substrate engagement to catalytic competence.","evidence":"Biochemical and biophysical dimerization/binding assays and crystal structures of the long isoform ± UFM1 with ATP","pmids":["29295865","30412706"],"confidence":"Medium","gaps":["physiological relevance of isoform-specific ATP regulation in cells untested","single-lab biophysical findings"]},{"year":2019,"claim":"Explained ATG8-family selectivity, showing the UBA5 LIR prefers GABARAP via a tryptophan inserting into a novel hydrophobic pocket and that GABARAP governs UBA5 ER localization independent of lipidation.","evidence":"NMR/X-ray structures of GABARAP–UBA5 LIR complexes, ITC, swapping mutagenesis, live-cell imaging/fractionation","pmids":["30990354"],"confidence":"High","gaps":["how ER-localized UBA5 selects membrane-proximal substrates unknown","functional integration with autophagy machinery undefined"]},{"year":2021,"claim":"Resolved the structural basis of UBA5-to-UFC1 transfer, showing an unconventional short linear C-terminal sequence positions UBA5 next to UFC1's active-site cysteine to compensate for a missing loop.","evidence":"X-ray and NMR structures of UBA5 C-terminus–UFC1 complexes with truncation/mutagenesis transfer assays","pmids":["34588452","34299007"],"confidence":"High","gaps":["transient catalytic intermediate of transthiolation not captured","regulation of C-terminal engagement in cells unknown"]},{"year":2021,"claim":"Characterized the directionality and oligomeric plasticity of the system, showing free UFM1 concentration controls transfer directionality and UBA5 undergoes concentration-dependent oligomeric transitions.","evidence":"Biochemical thioester and cell migration assays with overexpression/knockout lines; SAXS and biophysical oligomeric-state analysis","pmids":["35806453","34508858"],"confidence":"Medium","gaps":["physiological conditions controlling UFM1 pool size in cells undefined","SAXS oligomeric model from single study"]},{"year":2023,"claim":"Systematized genotype–phenotype relationships by building a biochemical allelic series whose loss-of-function severity correlates with in vivo phenotypes, providing a mechanistic framework for UBA5 disease variants.","evidence":"Comprehensive in vitro biochemical assays and a humanized Drosophila UBA5 model across an allelic series","pmids":["38079206"],"confidence":"High","gaps":["does not identify which downstream substrates drive specific clinical features","human cellular validation limited"]},{"year":2025,"claim":"Extended UBA5/UFM1 function to genome maintenance by identifying Ku70 as a UFMylation substrate whose modification promotes NHEJ DNA double-strand break repair.","evidence":"Photo-crosslinkable UFM1 probe, NMR, proximity proteomics, patient fibroblast assays, UFSP2 depletion (preprint)","pmids":["bio_10.1101_2025.06.16.659844"],"confidence":"Medium","gaps":["preprint, not yet peer-reviewed","in vivo relevance of NHEJ defect to disease phenotypes untested"]},{"year":2025,"claim":"Linked UBA5 to organelle quality control and neurodevelopmental disease mechanism, showing impaired mitophagy and GABAergic interneuron defects with exacerbated UPR in patient-derived models.","evidence":"UBA5 knockout cell mitophagy/ROS/cell-cycle assays and patient-derived cortical organoids with scRNA-seq and electrophysiology","pmids":["41645284","40333994"],"confidence":"Medium","gaps":["direct ufmylation substrate linking UBA5 to PINK1-Parkin mitophagy not identified","causal substrate for GABAergic defect unknown"]},{"year":null,"claim":"The full repertoire of physiological UFM1 substrates and how loss of individual ufmylation events maps onto distinct tissue phenotypes (erythroid, neuronal, mitochondrial, DNA repair) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["substrate-to-phenotype mapping incomplete","mechanism coupling ER-localized UBA5 to specific substrate selection unknown","regulation of pathway directionality in vivo undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,8]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,6,5]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[1,16]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[2,4]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[7,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,2,8]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[13,22]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[20]}],"complexes":[],"partners":["UFM1","UFC1","GABARAP","GABARAPL2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9GZZ9","full_name":"Ubiquitin-like modifier-activating enzyme 5","aliases":["ThiFP1","UFM1-activating enzyme","Ubiquitin-activating enzyme E1 domain-containing protein 1"],"length_aa":404,"mass_kda":44.9,"function":"E1-like enzyme which specifically catalyzes the first step in ufmylation (PubMed:15071506, PubMed:18442052, PubMed:20368332, PubMed:25219498, PubMed:26929408, PubMed:27545674, PubMed:27545681, PubMed:27653677, PubMed:30412706, PubMed:30626644, PubMed:34588452). Activates UFM1 by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a UFM1-E1 thioester and free AMP (PubMed:20368332, PubMed:26929408, PubMed:27653677, PubMed:30412706). Activates UFM1 via a trans-binding mechanism, in which UFM1 interacts with distinct sites in both subunits of the UBA5 homodimer (PubMed:27653677). Trans-binding also promotes stabilization of the UBA5 homodimer, and enhances ATP-binding (PubMed:29295865). Transfer of UFM1 from UBA5 to the E2-like enzyme UFC1 also takes place using a trans mechanism (PubMed:27653677, PubMed:34588452). Ufmylation plays a key role in various processes, such as ribosome recycling, response to DNA damage, interferon response or reticulophagy (also called ER-phagy) (PubMed:30412706, PubMed:32160526, PubMed:35394863). Ufmylation is essential for erythroid differentiation of both megakaryocytes and erythrocytes (By similarity)","subcellular_location":"Cytoplasm; Nucleus; Endoplasmic reticulum membrane; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/Q9GZZ9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/UBA5","classification":"Common Essential","n_dependent_lines":776,"n_total_lines":1208,"dependency_fraction":0.6423841059602649},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000081307","cell_line_id":"CID001785","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2},{"gene":"RPL32","stoichiometry":0.2},{"gene":"UFM1","stoichiometry":0.2},{"gene":"UFC1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001785","total_profiled":1310},"omim":[{"mim_id":"617899","title":"LEUKODYSTROPHY, HYPOMYELINATING, 14; HLD14","url":"https://www.omim.org/entry/617899"},{"mim_id":"617133","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 24; SCAR24","url":"https://www.omim.org/entry/617133"},{"mim_id":"617132","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 44; DEE44","url":"https://www.omim.org/entry/617132"},{"mim_id":"610553","title":"UBIQUITIN-FOLD MODIFIER 1; UFM1","url":"https://www.omim.org/entry/610553"},{"mim_id":"610552","title":"UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME 5; UBA5","url":"https://www.omim.org/entry/610552"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Vesicles","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/UBA5"},"hgnc":{"alias_symbol":["FLJ23251"],"prev_symbol":["UBE1DC1"]},"alphafold":{"accession":"Q9GZZ9","domains":[{"cath_id":"3.40.50.720","chopping":"75-321","consensus_level":"high","plddt":96.252,"start":75,"end":321}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9GZZ9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9GZZ9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9GZZ9-F1-predicted_aligned_error_v6.png","plddt_mean":86.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UBA5","jax_strain_url":"https://www.jax.org/strain/search?query=UBA5"},"sequence":{"accession":"Q9GZZ9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9GZZ9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9GZZ9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9GZZ9"}},"corpus_meta":[{"pmid":"21304510","id":"PMC_21304510","title":"The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice.","date":"2011","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/21304510","citation_count":150,"is_preprint":false},{"pmid":"27545681","id":"PMC_27545681","title":"Biallelic Variants in UBA5 Reveal that Disruption of the UFM1 Cascade Can Result in Early-Onset Encephalopathy.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27545681","citation_count":104,"is_preprint":false},{"pmid":"27545674","id":"PMC_27545674","title":"Biallelic Variants in UBA5 Link Dysfunctional UFM1 Ubiquitin-like Modifier Pathway to Severe Infantile-Onset Encephalopathy.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27545674","citation_count":101,"is_preprint":false},{"pmid":"28186401","id":"PMC_28186401","title":"Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target.","date":"2017","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/28186401","citation_count":87,"is_preprint":false},{"pmid":"26872069","id":"PMC_26872069","title":"UBA5 Mutations Cause a New Form of Autosomal Recessive Cerebellar Ataxia.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26872069","citation_count":79,"is_preprint":false},{"pmid":"20368332","id":"PMC_20368332","title":"Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzyme.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20368332","citation_count":69,"is_preprint":false},{"pmid":"26929408","id":"PMC_26929408","title":"Structural and Functional Analysis of a Novel Interaction Motif within UFM1-activating Enzyme 5 (UBA5) Required for Binding to Ubiquitin-like Proteins and Ufmylation.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26929408","citation_count":67,"is_preprint":false},{"pmid":"27653677","id":"PMC_27653677","title":"Trans-Binding Mechanism of Ubiquitin-like Protein Activation Revealed by a UBA5-UFM1 Complex.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27653677","citation_count":55,"is_preprint":false},{"pmid":"30990354","id":"PMC_30990354","title":"An atypical LIR motif within UBA5 (ubiquitin like modifier activating enzyme 5) interacts with GABARAP proteins and mediates membrane localization of UBA5.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30990354","citation_count":46,"is_preprint":false},{"pmid":"24966333","id":"PMC_24966333","title":"Mechanistic study of Uba5 enzyme and the Ufm1 conjugation pathway.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24966333","citation_count":43,"is_preprint":false},{"pmid":"29663568","id":"PMC_29663568","title":"Abnormal function of the UBA5 protein in a case of early developmental and epileptic encephalopathy with suppression-burst.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29663568","citation_count":39,"is_preprint":false},{"pmid":"34588452","id":"PMC_34588452","title":"Structural basis for UFM1 transfer from UBA5 to UFC1.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34588452","citation_count":38,"is_preprint":false},{"pmid":"28965491","id":"PMC_28965491","title":"Compound heterozygous mutations in UBA5 causing early-onset epileptic encephalopathy in two sisters.","date":"2017","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28965491","citation_count":36,"is_preprint":false},{"pmid":"30412706","id":"PMC_30412706","title":"An N-Terminal Extension to UBA5 Adenylation Domain Boosts UFM1 Activation: Isoform-Specific Differences in Ubiquitin-like Protein Activation.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30412706","citation_count":35,"is_preprint":false},{"pmid":"19101823","id":"PMC_19101823","title":"NMR and X-RAY structures of human E2-like ubiquitin-fold modifier conjugating enzyme 1 (UFC1) reveal structural and functional conservation in the metazoan UFM1-UBA5-UFC1 ubiquination pathway.","date":"2008","source":"Journal of structural and functional genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19101823","citation_count":32,"is_preprint":false},{"pmid":"32179706","id":"PMC_32179706","title":"A homozygous UBA5 pathogenic variant causes a fatal congenital neuropathy.","date":"2020","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32179706","citation_count":31,"is_preprint":false},{"pmid":"34572561","id":"PMC_34572561","title":"Inhibition of UBA5 Expression and Induction of Autophagy in Breast Cancer Cells by Usenamine A.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34572561","citation_count":31,"is_preprint":false},{"pmid":"27520940","id":"PMC_27520940","title":"A selective inhibitor of the UFM1-activating enzyme, UBA5.","date":"2015","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27520940","citation_count":30,"is_preprint":false},{"pmid":"18442052","id":"PMC_18442052","title":"UBE1DC1, an ubiquitin-activating enzyme, activates two different ubiquitin-like proteins.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18442052","citation_count":29,"is_preprint":false},{"pmid":"28360427","id":"PMC_28360427","title":"Novel insights into the interaction of UBA5 with UFM1 via a UFM1-interacting sequence.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28360427","citation_count":29,"is_preprint":false},{"pmid":"33811063","id":"PMC_33811063","title":"A description of novel variants and review of phenotypic spectrum in UBA5-related early epileptic encephalopathy.","date":"2021","source":"Cold Spring Harbor molecular case studies","url":"https://pubmed.ncbi.nlm.nih.gov/33811063","citation_count":28,"is_preprint":false},{"pmid":"30078785","id":"PMC_30078785","title":"Biallelic loss-of-function UBA5 mutations in a patient with intractable West syndrome and profound failure to thrive.","date":"2018","source":"Epileptic disorders : international epilepsy journal with videotape","url":"https://pubmed.ncbi.nlm.nih.gov/30078785","citation_count":22,"is_preprint":false},{"pmid":"29295865","id":"PMC_29295865","title":"Trans-binding of UFM1 to UBA5 stimulates UBA5 homodimerization and ATP binding.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29295865","citation_count":21,"is_preprint":false},{"pmid":"25084390","id":"PMC_25084390","title":"Characterization, crystallization and preliminary X-ray crystallographic analysis of the human Uba5 C-terminus-Ufc1 complex.","date":"2014","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/25084390","citation_count":17,"is_preprint":false},{"pmid":"16328888","id":"PMC_16328888","title":"Isolation and characterization of ubiquitin-activating enzyme E1-domain containing 1, UBE1DC1.","date":"2005","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/16328888","citation_count":16,"is_preprint":false},{"pmid":"38936760","id":"PMC_38936760","title":"UBA5 inhibition restricts lung adenocarcinoma via blocking macrophage M2 polarization and cisplatin resistance.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38936760","citation_count":15,"is_preprint":false},{"pmid":"33853163","id":"PMC_33853163","title":"Homozygous UBA5 Variant Leads to Hypomyelination with Thalamic Involvement and Axonal Neuropathy.","date":"2021","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/33853163","citation_count":15,"is_preprint":false},{"pmid":"34299007","id":"PMC_34299007","title":"A Concerted Action of UBA5 C-Terminal Unstructured Regions Is Important for Transfer of Activated UFM1 to UFC1.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299007","citation_count":15,"is_preprint":false},{"pmid":"38079206","id":"PMC_38079206","title":"Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/38079206","citation_count":10,"is_preprint":false},{"pmid":"35806453","id":"PMC_35806453","title":"Overexpression of UBA5 in Cells Mimics the Phenotype of Cells Lacking UBA5.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35806453","citation_count":10,"is_preprint":false},{"pmid":"38046095","id":"PMC_38046095","title":"Genetic model of UBA5 deficiency highlights the involvement of both peripheral and central nervous systems and identifies widespread mitochondrial abnormalities.","date":"2023","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/38046095","citation_count":9,"is_preprint":false},{"pmid":"40333994","id":"PMC_40333994","title":"Patient-derived models of UBA5-associated encephalopathy identify defects in neurodevelopment and highlight potential therapeutic avenues.","date":"2025","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40333994","citation_count":8,"is_preprint":false},{"pmid":"24915089","id":"PMC_24915089","title":"Characterization, crystallization and preliminary X-ray crystallographic analysis of the Uba5 fragment necessary for high-efficiency activation of Ufm1.","date":"2014","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/24915089","citation_count":5,"is_preprint":false},{"pmid":"34508858","id":"PMC_34508858","title":"Structure and dynamics of UBA5-UFM1 complex formation showing new insights in the UBA5 activation mechanism.","date":"2021","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/34508858","citation_count":4,"is_preprint":false},{"pmid":"38328212","id":"PMC_38328212","title":"Patient derived model of UBA5-associated encephalopathy identifies defects in neurodevelopment and highlights potential therapies.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38328212","citation_count":3,"is_preprint":false},{"pmid":"40217280","id":"PMC_40217280","title":"Developmental and epileptic encephalopathy 44 due to compound heterozygous variants in the UBA5 gene: a case report.","date":"2023","source":"Acta epileptologica","url":"https://pubmed.ncbi.nlm.nih.gov/40217280","citation_count":2,"is_preprint":false},{"pmid":"41645284","id":"PMC_41645284","title":"UBA5 deficiency disrupts mitochondrial autophagy via the PINK1-parkin pathway and impairs myoblast proliferation.","date":"2026","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/41645284","citation_count":1,"is_preprint":false},{"pmid":"41360240","id":"PMC_41360240","title":"UBA5 missense variants disrupt UFM1 activation: Structural, dynamic, and functional dissection.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41360240","citation_count":0,"is_preprint":false},{"pmid":"37502976","id":"PMC_37502976","title":"Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays.","date":"2023","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37502976","citation_count":0,"is_preprint":false},{"pmid":"40920053","id":"PMC_40920053","title":"UBA5-epileptic encephalopathy: new patient, a novel variant, and a review of epileptic phenotypes.","date":"2025","source":"Epileptic disorders : international epilepsy journal with videotape","url":"https://pubmed.ncbi.nlm.nih.gov/40920053","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.16.659844","title":"UFMylation orchestrates chromatin engagement of core NHEJ components to promote DNA double-strand break repair","date":"2025-06-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.16.659844","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.15.653649","title":"A genus-wide interaction atlas across NS4B orthologues identifies a conserved role for UFMylation in orthoflavivirus replication","date":"2025-05-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.15.653649","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.25.620379","title":"Identification and characterization of UBA5 inhibitors","date":"2024-10-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.25.620379","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.09.632082","title":"UFMylation promotes orthoflavivirus infectious particle production","date":"2025-01-09","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.09.632082","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":22316,"output_tokens":5667,"usd":0.075977,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14218,"output_tokens":4724,"usd":0.094595,"stage2_stop_reason":"end_turn"},"total_usd":0.170572,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structure of human UBA5 bound to ATP revealed that the catalytic cysteine (Cys250) is located within the adenylation domain in an alpha-helical motif, unlike other E1 enzymes where the active-site cysteine is in a separate flexible domain. Conformational changes associated with ATP binding provide insight into ubiquityl-enzyme thioester formation.\",\n      \"method\": \"X-ray crystallography with structural comparison to canonical E1 enzymes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure solved with functional mechanistic interpretation, published in rigorous journal\",\n      \"pmids\": [\"20368332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"UBA5 activates UFM1 via a two-step mechanism forming a binary covalent UBA5~UFM1 thioester (contrasting with Uba1's three-step ternary mechanism). UBA5 shows random ordered binding with UFM1 and ATP. Binding of ATP to the UBA5~UFM1 thioester is required for efficient transthiolation of UFM1 to UFC1. The pan-E1 inhibitor adenosine 5'-sulfamate (ADS) reacts with the UBA5~UFM1 thioester to form a tight-binding Ufm1-ADS adduct.\",\n      \"method\": \"In vitro thioester formation assay, ATP-PPi exchange assay, mechanism-based inhibitor studies, cellular assays in HCT116 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical assays including reconstitution and mechanistic inhibitor probes in a single rigorous study\",\n      \"pmids\": [\"24966333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure of the homodimeric UBA5 in complex with UFM1 revealed a trans-binding mechanism: UFM1 interacts with distinct sites on both subunits of the UBA5 dimer, requiring the C-terminal region to bring UFM1 to the active site of the adjacent subunit. Transfer of UFM1 from UBA5 to UFC1 (E2) also occurs via a trans mechanism requiring a UBA5 homodimer.\",\n      \"method\": \"X-ray crystallography of UBA5-UFM1 complex, supporting biochemical experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with biochemical validation of the trans mechanism\",\n      \"pmids\": [\"27653677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A combined LIR/UFIM motif at the C-terminus of UBA5 enables binding to both UFM1 and LC3/GABARAP proteins. This motif is required for full biological activity of UBA5 and for effective transfer of UFM1 onto UFC1 and downstream substrate proteins, both in vitro and in cells.\",\n      \"method\": \"NMR structure determination, binding assays, in vitro transfer assays, cellular functional assays with mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural determination combined with in vitro and cellular functional assays using mutants\",\n      \"pmids\": [\"26929408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of UFM1 fused to 13 amino acids of human UBA5 refined the UFM1-interacting sequence (UIS) boundaries. His336 of UBA5, not previously identified as part of the UIS, occupies a negatively charged pocket on UFM1's surface and is required for UFM1 binding and activation when mutated. A UFM1-UFM1 interaction was found to mimic UIS binding.\",\n      \"method\": \"X-ray crystallography, binding assays, UFM1 activation activity assays with mutagenesis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with mutagenesis-validated binding and activity assays\",\n      \"pmids\": [\"28360427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Trans-binding of UFM1 to UBA5 stabilizes the UBA5 homodimer, and UBA5 dimerization is required for ATP binding. UFM1 binding therefore enhances UBA5 affinity for ATP, establishing a regulatory connection between UFM1 engagement and ATP binding by UBA5.\",\n      \"method\": \"Biochemical binding and activity assays, biophysical analysis of dimerization\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical methods in single lab demonstrating mechanistic connection\",\n      \"pmids\": [\"29295865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The N-terminal extension present in the longer UBA5 isoform directly participates in ATP binding and changes the stoichiometry from 1:2 to 1:1 (ATP:UBA5), significantly increases UBA5 affinity for ATP, and stimulates transfer of UFM1 from UBA5 to UFC1 despite not being directly involved in E2 binding.\",\n      \"method\": \"Crystal structures of long UBA5 isoform ± UFM1 with ATP, biochemical ATP binding and UFM1 transfer assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures with biochemical validation in a single focused study\",\n      \"pmids\": [\"30412706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The non-canonical LIR motif of UBA5 preferentially interacts with GABARAP over LC3 proteins via an additional conserved tryptophan binding into a novel hydrophobic pocket (HP0) on GABARAP surface, with K/R47 in GABARAP as the key specificity residue. GABARAP proteins regulate UBA5 localization and function on the endoplasmic reticulum membrane in a lipidation-independent manner.\",\n      \"method\": \"NMR and X-ray crystal structures of GABARAP/GABARAPL2-UBA5 LIR complexes, swapping mutagenesis, isothermal titration calorimetry, live cell imaging/fractionation\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal/NMR structures, mutagenesis, and functional localization assays\",\n      \"pmids\": [\"30990354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structure of UFC1 bound to the C-terminus of UBA5 revealed a short linear sequence mediating the UBA5-UFC1 interaction not observed in other E1-E2 complexes. A region outside the adenylation domain of UBA5 is dispensable for UFC1 binding but critical for UFM1 transfer, moving next to UFC1's active-site Cys to compensate for a missing loop in UFC1.\",\n      \"method\": \"X-ray crystallography of UBA5 C-terminus–UFC1 complex, biochemical UFM1 transfer assays with truncation/mutagenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis-validated transfer mechanism\",\n      \"pmids\": [\"34588452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The last 20 residues of the C-terminal unstructured region of UBA5 are pivotal for binding to UFC1 and accelerate UFM1 transfer to UFC1. NMR structure of UFC1 bound to the last 20 residues of UBA5 revealed the molecular basis of this interaction.\",\n      \"method\": \"NMR spectroscopy of UFC1-UBA5 C-terminal peptide complex, isothermal titration calorimetry, biochemical transfer assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with ITC and biochemical activity assays\",\n      \"pmids\": [\"34299007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UFM1 regulates the oligomeric state of UBA5: mixtures of homodimers and heterotrimers are observed in solution, with the UBA5-UFM1 complex undergoing concentration-dependent oligomeric transitions. UBA5 alone transitions from monomeric to dimeric in a concentration-dependent manner with negative cooperativity in complex formation.\",\n      \"method\": \"Small-angle X-ray scattering (SAXS), binding studies, biophysical characterization of oligomeric states\",\n      \"journal\": \"Journal of structural biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — SAXS-based structural analysis, single lab, single study\",\n      \"pmids\": [\"34508858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Overexpression of UBA5 (but not UFC1) reverses the trans-thiolation reaction, causing back-transfer of UFM1 from UFC1 to UBA5, thereby reducing charged UFC1 levels and impairing ufmylation. This overexpression phenocopies UBA5 or UFC1 loss in impairing cell migration. Co-expression with UFM1 abolishes the back-transfer, indicating that free UFM1 concentration controls directionality.\",\n      \"method\": \"Biochemical thioester assays, cell migration assays with overexpression and knockout lines\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical and cellular assays with multiple genetic conditions in single lab\",\n      \"pmids\": [\"35806453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Uba5 is the specific E1-activating enzyme for UFM1 and is indispensable for erythroid differentiation in mice. Genetic loss of Uba5 impairs development of megakaryocyte and erythroid progenitors from common myeloid progenitors, causing severe anemia and embryonic death. Transgenic erythroid-specific re-expression of Uba5 rescued anemia, demonstrating cell-autonomous function.\",\n      \"method\": \"Conditional knockout mouse model, transgenic rescue, colony-forming assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with transgenic rescue demonstrating cell-autonomous mechanism, published in high-impact journal\",\n      \"pmids\": [\"21304510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"UBA5 mutations causing early-onset encephalopathy impair ufmylation and result in abnormal endoplasmic reticulum structure in patient fibroblasts. In C. elegans, knockout of uba-5 and UFM1 cascade orthologs alters cholinergic but not glutamatergic neurotransmission. In zebrafish, uba5 silencing decreases motility and induces seizure-like movements.\",\n      \"method\": \"Biochemical ufmylation assays in patient fibroblasts, C. elegans knockout behavioral assays, zebrafish morpholino knockdown\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — orthogonal model systems with functional assays, multiple cell and organism-level readouts\",\n      \"pmids\": [\"27545681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The UBA5 p.Ala371Thr variant is hypomorphic, with attenuated ability to transfer activated UFM1 to UFC1 as shown by in vitro thioester formation assay. CNS-specific knockout of Ufm1 in mice causes neonatal death with microcephaly and apoptosis in specific neurons.\",\n      \"method\": \"In vitro thioester formation assay, conditional CNS Ufm1 knockout mouse model\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro biochemical assay with mutagenesis combined with genetic mouse model\",\n      \"pmids\": [\"27545674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"UBA5-R246X mutation dramatically decreases protein half-life and abolishes UFM1 activation due to loss of the catalytic Cys250. UBA5-K310E maintains UFM1 interaction with reduced stability. In Drosophila, UBA5 knockdown induces locomotor defects, shortened lifespan, and aberrant neuromuscular junctions; wild-type but not mutant UBA5 restores neural lesions.\",\n      \"method\": \"Protein stability assays, UFM1 activation assays, Drosophila genetic rescue with wild-type vs. mutant UBA5\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical assays and genetic rescue in Drosophila model with mutant-specific comparisons\",\n      \"pmids\": [\"26872069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"UBA5 (UBE1DC1) activates not only UFM1 but also SUMO2 in vitro and in vivo by forming a high-energy thioester bond. UBA5 localizes predominantly to the cytoplasm, but redistributes to the nucleus upon co-transfection with SUMO2.\",\n      \"method\": \"In vitro thioester assay, in vivo co-immunoprecipitation, immunofluorescence subcellular localization in AD293 cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, SUMO2 activation finding not widely replicated; subcellular localization by single method\",\n      \"pmids\": [\"18442052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A covalent ligand (DKM 2-93) that modifies the catalytic cysteine of UBA5 inhibits its activity as an E1 enzyme for UFM1, impairs pancreatic cancer cell survival, and reduces in vivo tumor growth, identifying UBA5 catalytic cysteine as a druggable hotspot.\",\n      \"method\": \"isoTOP-ABPP chemoproteomic platform, covalent ligand screening, in vitro activity assays, cell viability assays, xenograft tumor models\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — chemoproteomic target identification with biochemical and in vivo functional validation\",\n      \"pmids\": [\"28186401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Systematic biochemical assays across UBA5 disease variants established an allelic series with mild, intermediate, and severe loss-of-function grades based on protein stability, ATP binding, UFM1 activation, and UFM1 transthiolation. In vivo Drosophila phenotypes (viability, lifespan, locomotion) strongly correlate with in vitro biochemical severity.\",\n      \"method\": \"Comprehensive in vitro biochemical assays (thermal stability, ATP binding, UFM1 charging, transthiolation), humanized Drosophila UBA5 model\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical assays combined with in vivo genetic model across allelic series\",\n      \"pmids\": [\"38079206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"UBA5 loss disrupts mitochondrial quality control: UBA5-deficient cells accumulate damaged mitochondria and increased ROS. The PINK1-Parkin damage response is engaged but mitophagy execution is inefficient, resulting in impaired clearance of dysfunctional mitochondria, p53 activation, DNA damage responses, p21-associated G2/M arrest, and early apoptosis.\",\n      \"method\": \"UBA5 knockout cells, mitochondrial morphology assays, ROS measurement, mitophagy flux assays, cell cycle analysis, apoptosis assays\",\n      \"journal\": \"Biological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple cellular assays in single study but limited mechanistic depth on UFMylation-PINK1/Parkin connection\",\n      \"pmids\": [\"41645284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UFMylation downstream of UBA5 promotes non-homologous end-joining (NHEJ) DNA double-strand break repair. Ku70 is identified as a UFMylation substrate; UFMylated Ku70 is recognized by XRCC4 to promote chromatin assembly of NHEJ factors. Perturbation via a hypomorphic UBA5 allele in patient-derived fibroblasts impairs these processes.\",\n      \"method\": \"Photo-crosslinkable UFM1 probe, high-resolution NMR, proximity-dependent proteomics, patient-derived fibroblast functional assays, UFSP2 depletion\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — multiple sophisticated methods but preprint, single study, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.06.16.659844\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBA5 function is required for orthoflavivirus (dengue, Zika, West Nile, yellow fever) replication. UFMylation pathway components including UBA5 are selectively recruited to viral replication sites; UFMylation promotes mitochondrial respiration in this context. Pharmacological inhibition of UFMylation reduces viral replication in vitro and in vivo.\",\n      \"method\": \"Proteomic interaction mapping, siRNA knockdown of UFMylation components, pharmacological inhibition, in vitro and in vivo viral replication assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, UBA5-specific mechanistic detail is limited relative to broader UFMylation pathway findings\",\n      \"pmids\": [\"bio_10.1101_2025.05.15.653649\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Patient-derived cortical organoids with compound heterozygous UBA5 pathogenic variants show defects in GABAergic interneuron development, aberrant neuronal firing, and reduced organoid size. ER homeostasis is perturbed and the unfolded protein response pathway is exacerbated in cells and organoids expressing UBA5 pathogenic variants.\",\n      \"method\": \"Patient-derived cortical organoid culture, single-cell RNA sequencing, electrophysiology, UPR pathway assays\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — humanized patient-derived model with multiple cellular readouts and mechanistic ER stress pathway analysis\",\n      \"pmids\": [\"40333994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"UBA5 residues 381–404 constitute the minimal region for UFC1 recognition, while residues 364–404 are necessary for transthiolation of UFM1 to UFC1. The UBA5–UFC1 fusion protein exists as a homodimer in solution.\",\n      \"method\": \"Truncation assays, protein biochemistry, crystallization/preliminary X-ray analysis\",\n      \"journal\": \"Acta crystallographica Section F\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — defined minimal binding region by truncation with structural corroboration, single study\",\n      \"pmids\": [\"25084390\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UBA5 is the sole E1-activating enzyme for UFM1 that functions as a homodimer using a two-step (binary thioester) mechanism distinct from canonical E1 enzymes: its catalytic Cys250 resides within the adenylation domain, UFM1 binds in trans across the dimer interface stabilizing dimerization and enhancing ATP binding, a C-terminal region (residues 381–404) mediates UFC1 binding and UFM1 transthiolation via an unconventional short linear motif, and an atypical LIR/UFIM motif targets UBA5 to the ER membrane through GABARAP interaction; loss of UBA5 activity causes ER stress, impaired mitophagy, defective erythroid differentiation, and aberrant neurodevelopment including GABAergic interneuron defects.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"UBA5 is the sole E1-activating enzyme that initiates the UFM1 conjugation (ufmylation) cascade, an essential post-translational modification system required for erythroid development, neurodevelopment, ER homeostasis, and genome maintenance [#12, #1]. It activates UFM1 through an unconventional two-step mechanism that forms a binary covalent UBA5~UFM1 thioester on its catalytic Cys250, which uniquely resides within the adenylation domain rather than a separate cysteine-bearing domain as in canonical E1 enzymes [#0, #1]. UBA5 functions as a homodimer that engages UFM1 in trans: UFM1 binds distinct sites across both subunits, stabilizing dimerization and enhancing ATP binding, and the C-terminal region delivers UFM1 to the active site of the adjacent subunit for transthiolation onto the E2 enzyme UFC1 [#2, #5]. A short linear motif in the C-terminal unstructured region (residues 381–404) mediates UFC1 recognition and positions UBA5 next to UFC1's active-site cysteine to drive UFM1 transfer, while an atypical combined LIR/UFIM motif binds both UFM1 and GABARAP, the latter targeting UBA5 to the ER membrane independent of lipidation [#8, #23, #7, #3]. Downstream of this cascade, UFM1 is conjugated to substrates including Ku70 to promote non-homologous end-joining DNA repair [#20]. Loss of UBA5 activity impairs ufmylation and produces ER stress and an exacerbated unfolded protein response, defective mitochondrial quality control with inefficient PINK1-Parkin mitophagy, defective erythroid differentiation, and aberrant neurodevelopment with GABAergic interneuron defects [#22, #19, #12]. Biallelic hypomorphic and loss-of-function UBA5 variants form a graded allelic series whose biochemical severity correlates with early-onset encephalopathy phenotypes [#18, #13].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established UBA5 as a thioester-forming activating enzyme, the founding observation of its E1 catalytic capacity, though with disputed substrate breadth.\",\n      \"evidence\": \"In vitro thioester assay, co-immunoprecipitation and immunofluorescence in AD293 cells\",\n      \"pmids\": [\"18442052\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"SUMO2 activation not widely replicated and conflicts with later UFM1-specific consensus\", \"subcellular localization assessed by single method\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Resolved why UBA5 is mechanistically atypical by placing its catalytic Cys250 within the adenylation domain rather than a separate cysteine domain, distinguishing it from canonical E1 enzymes.\",\n      \"evidence\": \"X-ray crystallography of human UBA5–ATP with comparison to canonical E1 enzymes\",\n      \"pmids\": [\"20368332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structure did not capture the UFM1-bound or transthiolation state\", \"dimeric trans mechanism not yet resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the physiological requirement for UBA5/UFM1 by showing it is indispensable and cell-autonomous for erythroid differentiation, establishing the pathway's developmental importance.\",\n      \"evidence\": \"Conditional knockout mouse with erythroid-specific transgenic rescue and colony-forming assays\",\n      \"pmids\": [\"21304510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"molecular ufmylation substrates in erythropoiesis not identified\", \"does not address neuronal phenotypes\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the kinetic logic of UFM1 activation, showing a two-step binary thioester mechanism with ATP-dependent transthiolation, and mapped the minimal UFC1-binding C-terminal region.\",\n      \"evidence\": \"In vitro thioester and ATP-PPi exchange assays, mechanism-based inhibitor probes, truncation analysis with HCT116 cellular assays\",\n      \"pmids\": [\"24966333\", \"25084390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis of UFM1-to-UFC1 transfer not yet visualized\", \"regulation of reaction directionality undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed that UBA5 operates as a homodimer engaging UFM1 in trans across the dimer interface, explaining how a single-domain E1 catalyzes both activation and transfer.\",\n      \"evidence\": \"X-ray crystallography of the UBA5–UFM1 complex with biochemical validation, plus refined UIS boundaries by additional crystallography and mutagenesis\",\n      \"pmids\": [\"27653677\", \"28360427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"dynamics of oligomeric transitions in solution not resolved\", \"coupling between dimerization and catalysis quantitatively undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected UBA5 to membrane targeting by defining a combined LIR/UFIM motif that binds both UFM1 and LC3/GABARAP and is required for full activity.\",\n      \"evidence\": \"NMR structure, binding assays, and in vitro/cellular transfer assays with mutagenesis\",\n      \"pmids\": [\"26929408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"functional consequence of ER localization not yet defined\", \"selectivity among ATG8 family members not yet resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked UBA5 to human disease by showing patient mutations impair ufmylation and disrupt ER structure, with model-organism phenotypes establishing a neurological role.\",\n      \"evidence\": \"Ufmylation assays in patient fibroblasts, C. elegans knockout behavior, zebrafish knockdown, in vitro thioester assays of variants, CNS Ufm1 mouse knockout\",\n      \"pmids\": [\"27545681\", \"27545674\", \"26872069\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"genotype–phenotype severity relationship not yet systematized\", \"neuronal substrates of ufmylation unidentified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established UBA5 as a druggable target by showing covalent modification of its catalytic cysteine blocks UFM1 activation and impairs cancer cell survival and tumor growth.\",\n      \"evidence\": \"isoTOP-ABPP chemoproteomics, covalent ligand screening, activity and viability assays, xenograft models\",\n      \"pmids\": [\"28186401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"selectivity over other cysteine-active enzymes not exhaustively characterized\", \"downstream ufmylation substrates mediating anti-tumor effect unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined regulatory coupling whereby UFM1 binding stabilizes the dimer and the long-isoform N-terminal extension tunes ATP affinity and stoichiometry, linking substrate engagement to catalytic competence.\",\n      \"evidence\": \"Biochemical and biophysical dimerization/binding assays and crystal structures of the long isoform ± UFM1 with ATP\",\n      \"pmids\": [\"29295865\", \"30412706\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"physiological relevance of isoform-specific ATP regulation in cells untested\", \"single-lab biophysical findings\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Explained ATG8-family selectivity, showing the UBA5 LIR prefers GABARAP via a tryptophan inserting into a novel hydrophobic pocket and that GABARAP governs UBA5 ER localization independent of lipidation.\",\n      \"evidence\": \"NMR/X-ray structures of GABARAP–UBA5 LIR complexes, ITC, swapping mutagenesis, live-cell imaging/fractionation\",\n      \"pmids\": [\"30990354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how ER-localized UBA5 selects membrane-proximal substrates unknown\", \"functional integration with autophagy machinery undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the structural basis of UBA5-to-UFC1 transfer, showing an unconventional short linear C-terminal sequence positions UBA5 next to UFC1's active-site cysteine to compensate for a missing loop.\",\n      \"evidence\": \"X-ray and NMR structures of UBA5 C-terminus–UFC1 complexes with truncation/mutagenesis transfer assays\",\n      \"pmids\": [\"34588452\", \"34299007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"transient catalytic intermediate of transthiolation not captured\", \"regulation of C-terminal engagement in cells unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Characterized the directionality and oligomeric plasticity of the system, showing free UFM1 concentration controls transfer directionality and UBA5 undergoes concentration-dependent oligomeric transitions.\",\n      \"evidence\": \"Biochemical thioester and cell migration assays with overexpression/knockout lines; SAXS and biophysical oligomeric-state analysis\",\n      \"pmids\": [\"35806453\", \"34508858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"physiological conditions controlling UFM1 pool size in cells undefined\", \"SAXS oligomeric model from single study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Systematized genotype–phenotype relationships by building a biochemical allelic series whose loss-of-function severity correlates with in vivo phenotypes, providing a mechanistic framework for UBA5 disease variants.\",\n      \"evidence\": \"Comprehensive in vitro biochemical assays and a humanized Drosophila UBA5 model across an allelic series\",\n      \"pmids\": [\"38079206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"does not identify which downstream substrates drive specific clinical features\", \"human cellular validation limited\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended UBA5/UFM1 function to genome maintenance by identifying Ku70 as a UFMylation substrate whose modification promotes NHEJ DNA double-strand break repair.\",\n      \"evidence\": \"Photo-crosslinkable UFM1 probe, NMR, proximity proteomics, patient fibroblast assays, UFSP2 depletion (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.06.16.659844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"preprint, not yet peer-reviewed\", \"in vivo relevance of NHEJ defect to disease phenotypes untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked UBA5 to organelle quality control and neurodevelopmental disease mechanism, showing impaired mitophagy and GABAergic interneuron defects with exacerbated UPR in patient-derived models.\",\n      \"evidence\": \"UBA5 knockout cell mitophagy/ROS/cell-cycle assays and patient-derived cortical organoids with scRNA-seq and electrophysiology\",\n      \"pmids\": [\"41645284\", \"40333994\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct ufmylation substrate linking UBA5 to PINK1-Parkin mitophagy not identified\", \"causal substrate for GABAergic defect unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The full repertoire of physiological UFM1 substrates and how loss of individual ufmylation events maps onto distinct tissue phenotypes (erythroid, neuronal, mitochondrial, DNA repair) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"substrate-to-phenotype mapping incomplete\", \"mechanism coupling ER-localized UBA5 to specific substrate selection unknown\", \"regulation of pathway directionality in vivo undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 8]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 6, 5]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [1, 16]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 2, 8]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [13, 22]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"UFM1\", \"UFC1\", \"GABARAP\", \"GABARAPL2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}